Sunday 18 October 2026
Export COYA’s income statement to Excel — free account
Coya Therapeutics, Inc.
COYA Healthcare Biotechnology
Coya Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.9 million, up 123.6% from fiscal 2024. In the quarter to June 2026, revenue grew 49.0%, EPS grew 22.2% and free cash flow fell 27.8%, each against the same quarter a year earlier.
4.27
0.07
−1.61%
Follow COYA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
23.92 | 12.21 | 11.24 | 17.11 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(84.36) | (96.35) | (14.37) | (18.60) | |
P/B ratio |
3.50 | 2.26 | 1.82 | 3.17 | |
Price to Tangible BV |
3.50 | 2.26 | 1.82 | 3.17 | |
EV/Sales |
20.11 | 7.95 | 6.48 | 13.34 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.61) | (5.88) | (3.64) | (6.81) | |
EV/FCF |
(6.34) | (5.31) | (3.18) | (6.02) | |
Quick Ratio |
7.67 | 7.97 | 14.30 | 12.29 | |
Current Ratio |
8.73 | 8.50 | 15.02 | 13.40 | |
Net Debt/EBITDA |
11.59 | 7.77 | 6.64 | 6.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.12 | 0.17 | 0.17 | 0.20 | |
Operating CF/Net income |
0.53 | 0.18 | 0.86 | 1.11 | |
Capex/Depreciation |
(75.88) | (94.00) | (316.07) | (0.61) | |
Research and Development Expense of Revenue |
81.84% | 124.76% | 1,631.46% | 2,064.30% | |
Selling, General and Administrative Expense of Revenue |
71.75% | 82.57% | 1,506.17% | 925.56% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
30.05% | 27.87% | 874.35% | 387.32% | |
Graham Net Nets |
0.29 | 0.44 | 0.55 | 0.31 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.47%) | (21.90%) | (29.19%) | (18.29%) | |
Free Cash Flow Yield |
(13.27%) | (12.27%) | (18.12%) | (12.95%) | |
Revenue per Share |
0.21 | 0.24 | 0.01 | 0.01 | |
Operating CF per Share |
(0.07) | (0.06) | (0.27) | (0.31) | |
Capex per Share |
(0.03) | (0.04) | (0.04) | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.10) | (0.31) | (0.31) | |
Cash per Share |
1.68 | 2.80 | 2.24 | 1.84 | |
Shareholders Equity per Share |
1.63 | 2.57 | 2.16 | 1.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.63 | 2.57 | 2.16 | 1.84 | |
Free Cash Flow |
(1.65) | (1.66) | (7.09) | (7.38) | |
Working Capital |
28.36 | 44.07 | 49.72 | 43.55 | |
Capital Expenditures |
(0.52) | (0.65) | (0.88) | 0.00 | |
Net Current Asset Value |
27.27 | 43.02 | 48.96 | 43.03 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.14 | 0.16 | 3.52 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.72 | 1.32 | 1.32 | 1.01 | |
Average Assets |
33.80 | 47.15 | 45.84 | 40.38 | |
Average Common Equity |
29.65 | 41.30 | 41.17 | 35.79 |
Columns are period end dates